Psychoactive fungi

New Wave Holdings Congratulates TheraPsil's Advocacy to Bring Psilocybin Therapy to Palliative Care for Canadian Patients

Retrieved on: 
Thursday, December 10, 2020
Psychoactive drugs, Health sciences, Entheogens, Psilocybe, Psilocybin therapy, Drug discovery, Psychoactive fungi, Psilocybin, Therapy, Legal status of psilocybin mushrooms, Psilocybin decriminalization in the United States

17 healthcare professionals associated with TheraPsil, a non-profit, patient-rights advocacy group, have been approved by the Federal Health Minister, Patty Hajdu, to possess and use psilocybin for professional training in psilocybin therapy.

Key Points: 
  • 17 healthcare professionals associated with TheraPsil, a non-profit, patient-rights advocacy group, have been approved by the Federal Health Minister, Patty Hajdu, to possess and use psilocybin for professional training in psilocybin therapy.
  • New Wave is proud to have sponsored TheraPsil in this journey and applaud the hard work conducted by the team and all the various partners involved.
  • TheraPsil is a non-profit coalition that advocates for legal, compassionate access to psilocybin therapy for Canadians in medical need.
  • TheraPsil, supports patients with their applications for ministerial approval of psilocybin for medical purposes and connects approved patients with qualified practitioners to receive psilocybin-assisted therapy treatment.

CaaMTech Expands Successful Next-Gen Drug Research Collaboration With UMass Dartmouth

Retrieved on: 
Wednesday, December 9, 2020
Entheogens, Psychoactive fungi, Psychoactive drugs, Psilocybin mushroom, Psychedelic drug, Psilocybin

"We have been consistently blown away by the results of CaaMTech's collaboration with Dr. Manke and his team at UMass Dartmouth," said Dr. Andrew Chadeayne , CEO of CaaMTech.

Key Points: 
  • "We have been consistently blown away by the results of CaaMTech's collaboration with Dr. Manke and his team at UMass Dartmouth," said Dr. Andrew Chadeayne , CEO of CaaMTech.
  • The research collaboration between CaaMTech and UMass Dartmouth has produced several classes of novel molecules.The library of compounds produced by the collaboration includes synthetic versions of naturally occurring tryptamine compounds found in psychedelic plants and fungi, such as psilocybin-containing "magic mushrooms.
  • The collaborative research between CaaMTech and UMass Dartmouth is foundational to the development of next-generation psychedelic medicines.
  • Through the collaboration with Dr. Manke and his team at UMass Dartmouth, CaaMTech continues to exponentially expand the menu of active ingredients for next-generation psychedelic drug products.

Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

Retrieved on: 
Tuesday, December 8, 2020
Entheogens, Psychoactive fungi, Psychoactive drugs, Psilocybin mushroom, Psilocybin

The Company is now preparing to export the harvest to its Canadian cGMP Facility which has a Health Canada schedule 1 Dealers License attached to it, allowing for legal import.

Key Points: 
  • The Company is now preparing to export the harvest to its Canadian cGMP Facility which has a Health Canada schedule 1 Dealers License attached to it, allowing for legal import.
  • We are pleased to announce the completion of our first commercial harvest of natural psilocybin mushrooms, said Joshua Bartch, CEO and Chairman of Mydecine.
  • Once received by the Companys facility in Canada, the psilocybin mushrooms will be extracted, refined and turned into a cGMP final product for controlled therapeutic purposes.
  • Mydecine Innovations Group is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

Retrieved on: 
Monday, December 7, 2020
Hallucinations, Entheogens, Psychoactive fungi, Psychedelic drug, Branches of biology

UAB is one of the few universities in the world currently investigating the medicinal benefits of psilocybin.

Key Points: 
  • UAB is one of the few universities in the world currently investigating the medicinal benefits of psilocybin.
  • Dr. Hendricks has served as Associate Professor at UAB since 2010.
  • His most current area of research focused on the evaluation of the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics.
  • Dr. Hendricks earned his Doctor of Philosophy from the University of South Florida in 2006.

REPEAT -- Pure Extracts Advances Plans for the Processing of Functional Mushroom Formulations

Retrieved on: 
Thursday, November 26, 2020
Entheogens, Fungi, Psychoactive fungi, Psychoactive drugs, Branches of biology, Non-timber forest products, Psilocybin mushroom, Hallucinations, Mushroom, Psilocybin, Shrooms, Psychedelic drug

Pure Extracts has noted recent announcements showing increased institutional interest in the field of psychedelics in general and with a focus on promising mushroom varieties such as psilocybin specifically.

Key Points: 
  • Pure Extracts has noted recent announcements showing increased institutional interest in the field of psychedelics in general and with a focus on promising mushroom varieties such as psilocybin specifically.
  • In that regard, Pure Extracts has signed a Letter of Intent (LOI) with one of Canadas leading functional mushroom wellness brands to co-develop CBD enhanced mushroom products.
  • Looking further ahead, Pure Extracts aims to eventually enter the growing field of psychedelic mushroom processing as an additional aspect of its diverse extraction market penetration strategy.
  • Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.

Pure Extracts Advances Plans for the Processing of Functional Mushroom Formulations

Retrieved on: 
Thursday, November 26, 2020
Entheogens, Fungi, Psychoactive fungi, Psychoactive drugs, Branches of biology, Non-timber forest products, Psilocybin mushroom, Hallucinations, Mushroom, Psilocybin, Shrooms, Psychedelic drug

Pure Extracts has noted recent announcements showing increased institutional interest in the field of psychedelics in general and with a focus on promising mushroom varieties such as psilocybin specifically.

Key Points: 
  • Pure Extracts has noted recent announcements showing increased institutional interest in the field of psychedelics in general and with a focus on promising mushroom varieties such as psilocybin specifically.
  • In that regard, Pure Extracts has signed a Letter of Intent (LOI) with one of Canadas leading functional mushroom wellness brands to co-develop CBD enhanced mushroom products.
  • Looking further ahead, Pure Extracts aims to eventually enter the growing field of psychedelic mushroom processing as an additional aspect of its diverse extraction market penetration strategy.
  • Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.

Silo Wellness Announces the First-of-Its-Kind U.S.-Legal Psychedelic Wellness Nature Retreat in Oregon

Retrieved on: 
Friday, November 13, 2020
Psychoactive drugs, Drugs, Entheogens, Neurochemistry, Psychoactive fungi, Psilocybin mushroom, Ketamine, Silo, Psilocybin, Shrooms

This will add to the existing psilocybin operations in Jamaica, where Silo currently has mushroom and truffle cultivation, as well as multiple psychedelic retreat offerings.

Key Points: 
  • This will add to the existing psilocybin operations in Jamaica, where Silo currently has mushroom and truffle cultivation, as well as multiple psychedelic retreat offerings.
  • A short flight from Seattle and San Francisco, and less than a 2.5-hour drive from Portland, Silos first Oregon retreat will allow qualifying participants to experience Ketamine-assisted wellness benefits alongside nature.
  • Oregon Attorney Mike Arnold, founder of Silo Wellness, stated, We are very excited about the opportunity that Oregon, being the first state to legalize psychedelic mushrooms, presents Silo.
  • The Silo Wellness team is also offering this unique opportunity to Oregon physicians working in the ketamine space.

Critical Election Day Victories for Psychedelics Continue the Industry’s Momentum 

Retrieved on: 
Monday, November 9, 2020
Hallucinations, Psychedelic drug, Psychoactive fungi

Congratulations to Tom and Sheri Eckert for the tireless work they have put into Measure 109, said Flores.

Key Points: 
  • Congratulations to Tom and Sheri Eckert for the tireless work they have put into Measure 109, said Flores.
  • We are honored to have had the opportunity to share the important mission and message associated with Measure 109 through our Psychedelic Spotlight platform.
  • And with this passage, DC joins other cities including Denver, Oakland, and Santa Cruz, Calif., and Ann Arbor, Mich., which have already decriminalized plant and fungi-based psychedelics.
  • We support a harm reduction approach for the purpose of education and promoting individual and public safety.

Field Trip Health Ltd. Prepares to Enter Oregon Market following the Passage of Measure 109 in Oregon, Creating the First Legal Market for Psilocybin Services

Retrieved on: 
Thursday, November 5, 2020
Psychoactive drugs, Entheogens, Psychoactive fungi, Trip, Psilocybin, Psychedelic drug

Based on its geography and climate, Oregon is an ideal place for cultivation of psilocybin-producing mushrooms.

Key Points: 
  • Based on its geography and climate, Oregon is an ideal place for cultivation of psilocybin-producing mushrooms.
  • But cultivation that meets all quality standards and analytical testing requirements is complex, said Marshall Tyler, Field Trips Director of Research.
  • The success of Measure 109 validates that belief, and positions us to be the clear leader in the emerging psychedelics industry.
  • About Field Trip Health Ltd.
    Field Trip is the global leader in the development and delivery of psychedelic therapies.

Allied Expands Pharmaceutical Pipeline By Filing US Provisional Patent for Psilocybin Based Therapeutics

Retrieved on: 
Tuesday, October 20, 2020
Entheogens, Psychoactive fungi, Psychoactive drugs, Articles, Branches of biology, Psilocybin, Psychedelic drug, Drug, Post-traumatic stress disorder, Shrooms

The provisional patent application covers a novel combination of psilocybin and proprietary mushroom formulation, as well as a novel treatment regimen targeting Post Traumatic Stress (PTSD), Depression and General Anxiety.

Key Points: 
  • The provisional patent application covers a novel combination of psilocybin and proprietary mushroom formulation, as well as a novel treatment regimen targeting Post Traumatic Stress (PTSD), Depression and General Anxiety.
  • Psilocybin is the active pharmaceutical ingredient contained in the Golden Teacher psychedelic mushroom.
  • Adding the psilocybin pharmaceutical product leverages our clinical trial expertise and infrastructure while simultaneously broadening our product offering beyond cannabis, said Calum Hughes, CEO of Allied.
  • With this provisional patent application, we have deepened our pharmaceutical pipeline in our key therapeutic areas of PTSD, Depression and General Anxiety.